Literature DB >> 28566423

Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts.

Miles A Miller1,2, Ravi Chandra1,3, Michael F Cuccarese1, Christina Pfirschke1, Camilla Engblom1, Shawn Stapleton1, Utsarga Adhikary1, Rainer H Kohler1, James F Mohan1, Mikael J Pittet1,2, Ralph Weissleder4,2,5.   

Abstract

Efficient delivery of therapeutic nanoparticles (TNPs) to tumors is critical in improving efficacy, yet strategies that universally maximize tumoral targeting by TNP modification have been difficult to achieve in the clinic. Instead of focusing on TNP optimization, we show that the tumor microenvironment itself can be therapeutically primed to facilitate accumulation of multiple clinically relevant TNPs. Building on the recent finding that tumor-associated macrophages (TAM) can serve as nanoparticle drug depots, we demonstrate that local tumor irradiation substantially increases TAM relative to tumor cells and, thus, TNP delivery. High-resolution intravital imaging reveals that after radiation, TAM primarily accumulate adjacent to microvasculature, elicit dynamic bursts of extravasation, and subsequently enhance drug uptake in neighboring tumor cells. TAM depletion eliminates otherwise beneficial radiation effects on TNP accumulation and efficacy, and controls with unencapsulated drug show that radiation effects are more pronounced with TNPs. Priming with combined radiation and cyclophosphamide enhances vascular bursting and tumoral TNP concentration, in some cases leading to a sixfold increase of TNP accumulation in the tumor, reaching 6% of the injected dose per gram of tissue. Radiation therapy alters tumors for enhanced TNP delivery in a TAM-dependent fashion, and these observations have implications for the design of next-generation tumor-targeted nanomaterials and clinical trials for adjuvant strategies.
Copyright © 2017, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28566423      PMCID: PMC6681815          DOI: 10.1126/scitranslmed.aal0225

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  38 in total

1.  Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation.

Authors:  Ruslan Hlushchuk; Oliver Riesterer; Oliver Baum; Jeanette Wood; Guenther Gruber; Martin Pruschy; Valentin Djonov
Journal:  Am J Pathol       Date:  2008-09-11       Impact factor: 4.307

2.  Gadolinium chloride augments tumor-specific imaging of targeted quantum dots in vivo.

Authors:  Parmeswaran Diagaradjane; Amit Deorukhkar; Juri G Gelovani; Dipen M Maru; Sunil Krishnan
Journal:  ACS Nano       Date:  2010-07-27       Impact factor: 15.881

3.  Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas.

Authors:  Sam S Yoon; Dan G Duda; Daniel L Karl; Tae-Min Kim; Avinash R Kambadakone; Yen-Lin Chen; Courtney Rothrock; Andrew E Rosenberg; G Petur Nielsen; David G Kirsch; Edwin Choy; David C Harmon; Francis J Hornicek; Jonathan Dreyfuss; Marek Ancukiewicz; Dushyant V Sahani; Peter J Park; Rakesh K Jain; Thomas F Delaney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-06       Impact factor: 7.038

4.  Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.

Authors:  Charles F Albright; Nilsa Graciani; Wei Han; Eddy Yue; Ross Stein; Zhihong Lai; Melody Diamond; Randine Dowling; Lisa Grimminger; Shu-Yun Zhang; Davette Behrens; Amy Musselman; Robert Bruckner; Mingzhu Zhang; Xiang Jiang; Daniel Hu; Anne Higley; Susan Dimeo; Maria Rafalski; Sandya Mandlekar; Bruce Car; Swamy Yeleswaram; Andrew Stern; Robert A Copeland; Andrew Combs; Steve P Seitz; George L Trainor; Rebecca Taub; Pearl Huang; Allen Oliff
Journal:  Mol Cancer Ther       Date:  2005-05       Impact factor: 6.261

5.  Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy.

Authors:  Pierre Sonveaux; Agnès Brouet; Xavier Havaux; Vincent Grégoire; Chantal Dessy; Jean-Luc Balligand; Olivier Feron
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

6.  Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation.

Authors:  Sergey V Kozin; Walid S Kamoun; Yuhui Huang; Michelle R Dawson; Rakesh K Jain; Dan G Duda
Journal:  Cancer Res       Date:  2010-07-14       Impact factor: 12.701

7.  The radiation-induced cell-death signaling pathway is activated by concurrent use of cisplatin in sequential biopsy specimens from patients with cervical cancer.

Authors:  Mayumi Iwakawa; Tatsuya Ohno; Kaori Imadome; Miyako Nakawatari; Ken-ichi Ishikawa; Minako Sakai; Shingo Katoh; Hitoshi Ishikawa; Hirohiko Tsujii; Takashi Imai
Journal:  Cancer Biol Ther       Date:  2007-03-05       Impact factor: 4.742

8.  Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies.

Authors:  Ande Bao; Beth Goins; Robert Klipper; George Negrete; William T Phillips
Journal:  J Pharmacol Exp Ther       Date:  2003-11-10       Impact factor: 4.030

9.  [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model.

Authors:  Anuradha Soundararajan; Ande Bao; William T Phillips; Ricardo Perez; Beth A Goins
Journal:  Nucl Med Biol       Date:  2009-05-07       Impact factor: 2.408

10.  Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy.

Authors:  Yuru Meng; Michael A Beckett; Hua Liang; Helena J Mauceri; Nico van Rooijen; Kenneth S Cohen; Ralph R Weichselbaum
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

View more
  76 in total

1.  Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using 64Cu-Labeled Macrin.

Authors:  Hye-Yeong Kim; Ran Li; Thomas S C Ng; Gabriel Courties; Christopher Blake Rodell; Mark Prytyskach; Rainer H Kohler; Mikael J Pittet; Matthias Nahrendorf; Ralph Weissleder; Miles A Miller
Journal:  ACS Nano       Date:  2018-12-11       Impact factor: 15.881

2.  Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics.

Authors:  Ran Li; Adel Attari; Mark Prytyskach; Michelle A Garlin; Ralph Weissleder; Miles A Miller
Journal:  Cytometry A       Date:  2019-08-19       Impact factor: 4.355

3.  Near infrared imaging of Mer tyrosine kinase (MERTK) using MERi-SiR reveals tumor associated macrophage uptake in metastatic disease.

Authors:  Miles A Miller; Eunha Kim; Michael F Cuccarese; Alec L Plotkin; Mark Prytyskach; Rainer H Kohler; Mikael J Pittet; Ralph Weissleder
Journal:  Chem Commun (Camb)       Date:  2017-12-19       Impact factor: 6.222

4.  TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.

Authors:  Christopher B Rodell; Sean P Arlauckas; Michael F Cuccarese; Christopher S Garris; Ran Li; Maaz S Ahmed; Rainer H Kohler; Mikael J Pittet; Ralph Weissleder
Journal:  Nat Biomed Eng       Date:  2018-05-21       Impact factor: 25.671

Review 5.  Tumor targeting via EPR: Strategies to enhance patient responses.

Authors:  Susanne K Golombek; Jan-Niklas May; Benjamin Theek; Lia Appold; Natascha Drude; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2018-07-19       Impact factor: 15.470

Review 6.  Enhancing cancer immunotherapy with nanomedicine.

Authors:  Darrell J Irvine; Eric L Dane
Journal:  Nat Rev Immunol       Date:  2020-01-31       Impact factor: 53.106

7.  Smart cancer nanomedicine.

Authors:  Roy van der Meel; Einar Sulheim; Yang Shi; Fabian Kiessling; Willem J M Mulder; Twan Lammers
Journal:  Nat Nanotechnol       Date:  2019-11-06       Impact factor: 39.213

Review 8.  Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.

Authors:  John D Martin; Horacio Cabral; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2020-02-07       Impact factor: 66.675

Review 9.  The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.

Authors:  Costas D Arvanitis; Gino B Ferraro; Rakesh K Jain
Journal:  Nat Rev Cancer       Date:  2019-10-10       Impact factor: 60.716

Review 10.  Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care.

Authors:  Christopher M Hartshorn; Michelle S Bradbury; Gregory M Lanza; Andre E Nel; Jianghong Rao; Andrew Z Wang; Ulrich B Wiesner; Lily Yang; Piotr Grodzinski
Journal:  ACS Nano       Date:  2017-12-22       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.